During cholesterol management, some people notice a pattern:
Levels go down for a period of time,
but later rise again.
These repeated fluctuations can be confusing.
Even with dietary control and regular exercise, maintaining stable levels may still be challenging.
At first glance, this may seem related to consistency.
However, at a deeper level, it is closely linked to the body’s internal regulatory mechanisms.
After discovering elevated cholesterol levels, many people begin making changes such as adjusting their diet, reducing fat intake, and increasing physical activity.
However, after some time, results may show little improvement. In some cases, levels remain high or fluctuate repeatedly.
This situation is not uncommon.
The issue is often not a lack of effort, but rather that cholesterol levels are influenced by more than just lifestyle habits.
Cancer is one of the leading causes of death worldwide and in Hong Kong. Many people are concerned about everyday “carcinogens” and wonder whether dietary changes, such as a low-carb diet, can help prevent or fight cancer. This article clarifies four widespread cancer myths from an integrative medicine viewpoint, highlighting the importance of optimising the body’s metabolic environment.
Many people feel concerned when they hear the word “cholesterol,” assuming it is harmful and that “the lower, the better.” In reality, cholesterol is an essential substance for the human body, and every cell can produce it. It plays a key role in building cell membranes, producing hormones (estrogen, testosterone, cortisol), synthesizing vitamin D, and supporting brain function. The belief that cholesterol should always be minimized is a common misconception.
Many people, especially older adults in Hong Kong, become anxious when they see a blood pressure reading of 150. Understanding the difference between occasional high blood pressure and actual hypertension is important for proper management.
Cancer remains one of the leading global health threats. Many patients undergo surgery, chemotherapy, or radiotherapy believing the cancer cells have been completely eliminated, only to discover recurrence or metastasis months or even years later. This phenomenon often causes confusion and anxiety. Medically, this is known as cancer recurrence or metastasis. It does not necessarily mean the initial treatment failed, but rather reflects the complex nature of cancer and the influence of the body’s overall metabolic environment.
Why Does High-Dose Intravenous Vitamin C Work for Some Cancer Patients but Not Others? High-dose intravenous vitamin C (HDIVC, also known as pharmacological ascorbate) used
When discussing cholesterol, many people hear the terms “good cholesterol” and “bad cholesterol.”
In reality, cholesterol itself is neither good nor bad—the key difference lies in how it is transported and used in the body.
Have you ever seen LDL and HDL on a health report but weren’t sure what they mean?
Understanding the difference between them is an important step in recognizing lipid balance.
High-dose intravenous vitamin C (HDIVC), also known as pharmacological ascorbate, has re-emerged in oncology research as a promising adjunctive supportive therapy. While it is not a standalone cure for cancer, clinical studies indicate that when administered at appropriate pharmacological doses, it can provide meaningful benefits for some patients—including improved survival in specific contexts, better quality of life (QoL), and reduced chemotherapy-related side effects. However, not every patient experiences the same level of improvement. This variability is not necessarily evidence that HDIVC “does not work,” but often reflects differences in how the therapy is implemented: dosage, frequency, integration with other treatments, practitioner expertise, and individual patient factors. The same method can yield very different outcomes depending on these variables.
In cholesterol management, people are often concerned not only about whether a method exists, but also:
Can it be maintained consistently?
Is it suitable for long-term management?
Can the body adapt to it over time?
With the emergence of newer approaches such as LEQVIO (Inclisiran),
the conversation is gradually shifting from short-term changes to long-term management outcomes.
So, based on publicly available clinical data, how should we understand its effectiveness and safety?